Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management
- 11 April 2016
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 35 (2) , 333-346
Abstract
The skeleton is frequently a secondary growth site of disseminated cancers, often leading to painful and devastating clinical outcomes. Metastatic cancer distorts bone marrow homeostasis through tumor-derived factors, which shapes different bone tumor microenvironments depending on the tumor cells’ origin. Here, we propose a novel insight on tumor-secreted Galectin-3 (Gal-3) that controls the induction of an inflammatory cascade, differentiation of osteoblasts, osteoclasts, and bone marrow cells, resulting in bone destruction and therapeutic failure. In the approaching era of personalized medicine, the current treatment modalities targeting bone metastatic environments are provided to the patient with limited consideration of the cancer cells’ origin. Our new outlook suggests delivering individual tumor microenvironment treatments based on the expression level/activity/functionality of tumor-derived factors, rather than utilizing a commonly shared therapeutic umbrella. The notion of “Gal-3-associated bone remodeling” could be the first step toward a specific personalized therapy for each cancer type generating a different bone niche in patients afflicted with non-curable bone metastasis.Keywords
This publication has 98 references indexed in Scilit:
- Prostate Cancer Cells and Bone Stromal Cells Mutually Interact with Each Other through Bone Morphogenetic Protein-mediated SignalsJournal of Biological Chemistry, 2012
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast ProgenitorsCancer Cell, 2011
- The bone marrow compartment is modified in the absence of galectin-3Cell and tissue research, 2011
- Steps in prostate cancer progression that lead to bone metastasisInternational Journal of Cancer, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone CellsCancer Cell, 2011
- Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesisJournal of Bone and Mineral Research, 2010
- Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic miceInternational Journal of Cancer, 2009
- Regulation of Tumor Progression by Extracellular Galectin-3Cancer Microenvironment, 2008